Director, US Medical Affairs, Medical Evidence Transformation

Join a Legacy of Innovation 125 Years and Counting!

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 125 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 18,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

Summary

The role of the Director, US Medical Affairs, Medical Evidence Transformation will be responsible for analyzing qualitative and quantitative data, identifying areas for medical improvement through social research, and implementing Real World Data (RWD)-driven strategies to enhance regional outcomes toward approved guidelines and consensus. This role focuses on maintaining and improving quality, ensuring compliance with standards, and promoting a culture of continuous improvement.
Make your application after reading the following skill and qualification requirements for this position.
Responsibilities
- Pinpoint specific external medical issues or gaps across approved Daiichi Sankyo therapeutic agents and the procedural system barriers that exist preventing medical optimization, including but not limited to collecting, analyzing, and interpreting data to identify trends, patterns, and areas where improvements can be made, and being an active participant in Integrated Evidence Planning (IEP) across the US Medical Teams, in conjunction with the Daiichi Sankyo US Business, and the Daiichi Sankyo Global IEP network.
- Work cross-functionally within US Medical Affairs (specifically with the relevant Health Economics, Outcomes Research, and Real-World Evidence teammates), and US Market Access to gather input, share information, and ensure alignment on medical transformation goals to develop and implement initiatives to address identified issues.
- Track and measure the impact of quality improvement, ensuring that improvements are sustained. This includes but is not limited to measuring how external healthcare systems have streamlined and improved existing processes to improve adherence to guidelines, consensus and protocols that may impact the US Medical Affairs objectives and the US Oncology Business Division key performance indicators.
- Regularly effectively communicate progress and results so that internal and external discussions are informative, motivating, and translatable to the Daiichi Sankyo US Business division. This includes but is not limited to analyzing results coherently for inclusion in clinical study reports, value dossiers and publications, and conducting post-hoc analyses of clinical data as necessary to develop value proposition for external stakeholders.

Qualifications : Successful candidates will be able to meet the qualifications below with or without a reasonable accommodation.

Education Qualifications (from an accredited college or university)
- Bachelor's Degree required
- Master's Degree Completed or Master's-Prepared in Public Health, research, analytics, Quality Systems & Improvement, or comparable field preferred

Experience Qualifications
- 10 or More Years overall related work experience required
- 4 or More Years data analysis,